CDC25A and glioblastoma: We revealed that levels of Cdc25A Y59 phosphorylation in samples from patients (30 cases) with low-grade diffuse astrocytoma (WHO grade II; median survival time >5 years) were significantly lower than those from patients with high-grade GBM (Fig. 7c)35.